Table 1 Selected genetic alterations representing potential biomarkers in lung adenocarcinoma and related drugs in clinical development
Biomarker | Drug |
|---|---|
EGFR mutations* | Gefitinib/Erlotinib/Afatinib |
ALK rearrangements* | Crizotinib |
ROS-1 rearrangements | Crizotinib |
RET rearrangements | Cabozantinib/Vandetanib/Ponatinib |
NTRK1 rearrangements | Cabozantinib |
MET amplification | Crizotinib/Cabozantinib |
NRAS mutations | Selumetinib/Trametinib |
ErbB-2 mutations/amplification | Lapatinib/Trastuzuma/Afatinib |
KRAS mutations | Selumetinib/Trametinib |
BRAF V600E | Vemurafenib/Dabrafenib |
BRAF Y472C | Dasatinib |